PTGS2 and colorectal carcinoma: Here we demonstrated that BRAFV600E CRC cells overcome BRAF ± MEK or EGFR therapies by upregulating a prosurvival, autocrine/oncocrine COX2–PGE2–GNAS–SRC–β-catenin signaling loop.